ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...
Oppenheimer analysts maintained a Perform rating on ResMed (NYSE:RMD) following the company's financial results for the second quarter of fiscal year 2025. ResMed reported a revenue increase of 10% ...
Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback